Gulati S C, Gopal R, Prowda J B, Spanik S, Jain M, Gopal A
Division of Hematology Oncology, Cornell University Medical College, New York, NY 10021.
Med Oncol. 1994;11(1):1-6. doi: 10.1007/BF02990084.
Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin, etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoietic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim, etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.
造血生长因子（粒细胞集落刺激因子、粒细胞-巨噬细胞集落刺激因子、促红细胞生成素等）的可获得性开启了剂量强化的新领域。此类生长因子的使用已使癌症患者的造血恢复加快，目前还带来了几种新的治疗调整方法。这些方法包括：（1）在无造血干细胞支持的情况下进行剂量强化；（2）在清髓性治疗和干细胞移植（异基因或自体）后加快造血恢复；（3）使用生长因子组合；以及（4）改善对造血细胞有毒性的抗菌药物（更昔洛韦、复方磺胺甲恶唑等）的给药方式。上述治疗策略正在积极进行临床试验，可为治疗癌症患者提供改进的、具有成本效益的方法。
